BIOLASE TECHNOLOGY INC (BLTI:undefined)
Snapshot of BIOLASE TECHNOLOGY INC (BLTI)
|
OPEN
$1.60
|
PREVIOUS CLOSE
$1.62
|
|
|
DAY HIGH
$1.70
|
DAY LOW
$1.58
|
|
|
52 WEEK HIGH
08/6/09 - $2.88
|
52 WEEK LOW
06/3/09 - $1.38
|
|
|
MARKET CAP
41.2M
|
AVERAGE VOLUME 10 D
42.2K
|
|
|
EPS TTM
$-0.14
|
SHARES OUTSTANDING
24.4M
|
|
|
EX-DATE
08/22/05
|
P/E TTM
--
|
|
|
DIVIDEND
--
|
DIVIDEND YIELD
--
|
|
| K = Thousands M = Millions B = Billions | ||
BLTI Details
BIOLASE Technology, Inc., a medical technology company, develops, manufactures, and markets lasers and related products and services focused on technologies for applications and procedures in dentistry and medicine. Its principal products are dental laser systems that allow general dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. The company offers two categories of laser system products comprising Waterlase family of products and Diode family of products. The Waterlase systems use a combination of water and laser to perform dental procedures for cutting soft and hard tissue plus bone. Its Waterlase systems include Waterlase MD and Waterlase C100 All-Tissue Dental Laser systems. The Diode systems use a semiconductor diode laser to perform soft tissue, hygiene, and cosmetic procedures, including teeth whitening, as well as pain management therapy. Its Diode systems consist of the ezlase, iLase, and Diolase 10 systems. The company also provides related accessories and disposable products for its laser systems, which include disposable laser tips, flexible fibers, hand pieces, and tooth whitening gel kits. BIOLASE Technology, Inc. sells its products through direct sales force and a network of independent distributors in the United States and internationally. The company was formerly known as Societe Endo Technic, SA and changed its name to BIOLASE Technology, Inc. in 1994. BIOLASE Technology, Inc. was founded in 1984 and is headquartered in Irvine, California.
BLTI Top Compensated Officers
Key developments for BIOLASE TECHNOLOGY INC (BLTI)
Biolase Technology, Inc. announced that it has entered into a $5 million secured debt facility with MidCap Financial, LLC and Silicon Valley Bank. BIOLASE received a first tranche of $3 million at closing, with a second tranche of $2 million, available upon completion of certain conditions. The financing will be used for ongoing working capital requirements.
Biolase Technology, Inc. announced that on May 20, 2010, the company entered into a license agreement with The Procter & Gamble Company, with an effective date of January 1, 2009, and which supersedes that certain prior license agreement, dated January 24, 2007, by and between the company and P&G.; The second agreement amends and modifies the first agreement so as to enable the company to launch and market for sale certain light-based oral care devices to dental professionals within the professional market. The Second Agreement will terminate on the date of expiration of the last Company or P&G; patent that is licensed to the other party, and the exclusivity of the Company's license to P&G; has certain limits and conditions. Additionally, either party may terminate the Second Agreement if there is an uncured material breach of any provision of the Second Agreement by the other party. The Second Agreement may also be terminated by mutual consent.
Biolase Technology, Inc. announced earnings results for the first quarter ended March 31, 2010. For the quarter, the company reported net loss of $5.3 million or $0.22 basic and diluted per share compared to $4.7 million or $0.19 basic and diluted per share, in the 2009 first quarter. Non-GAAP net loss was $4.8 million or $0.20 basic and diluted per share compared with non-GAAP net loss of $3.8 million or $0.15 basic and diluted per share for the similar quarter in 2009. Net revenue was $4.3 million compared to $6.5 million for the same period last year. Loss from operations was $5.3 million compared to $4.9 million for the same period last year. Loss before income tax provision of $5.2 million compared to $4.6 million for the same period last year.
Stock Quotes
| Recently Viewed | |||
| BLTI:US | $1.69 USD | +0.07 |  |
|---|---|---|---|
| SBUX:US | $25.89 USD | -0.13 |  |
| NAVR:US | $1.96 USD | +0.01 |  |
| RROLQ:US | $0.00 USD | 0.00 |  |
| NTAP:US | $37.68 USD | -0.49 |  |
Market data is delayed at least 15 minutes.
Business Exchange
Track and share business topics across the Web.
BLTI Competitors
| Company | Last | Change |
| Syneron Medical Ltd | $10.46 USD | +0.19 |
| View Industry Companies | ||
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | BLTI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.9x |
|
| Price/Book | 5.2x |
Not meaningful
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.9x |
|
|
BLTI |
||
BLTI transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Companies Toolbox
Update/report
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Ashburn, VA-Hhmi - Janelia Farm Research Campus
- Vienna, VA-Carl Marks
- Beverly Hills, CA-Live Nation Merchandise
- New York, NY-Meltwater Group
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For BIOLASE TECHNOLOGY INC (BLTI) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
